Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy()()

por Shahwan, K.T., Kimball, A.B.
Publicado en Int J Womens Dermatol (2016)

The validity of the diagnostic code for hidradenitis suppurativa in an electronic database

por Kim, G. E., Shlyankevich, J., Kimball, A. B.
Publicado en Br J Dermatol (2014)

An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life()()

por Storer, M.A., Danesh, M.J., Sandhu, M.E., Pascoe, V., Kimball, A.B.
Publicado en Int J Womens Dermatol (2018)

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

por Kimball, A.B., Crowley, J.J., Papp, K., Calimlim, B., Duan, Y., Fleischer, A.B., Sobell, J.
Publicado en J Eur Acad Dermatol Venereol (2020)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III stu...

por Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Publicado en Br J Dermatol (2019)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

por Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Publicado en Br J Dermatol (2019)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

por Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Publicado en J Eur Acad Dermatol Venereol (2018)

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled...

por Kimball, A.B., Sobell, J.M., Zouboulis, C.C., Gu, Y., Williams, D.A., Sundaram, M., Teixeira, H.D., Jemec, G.B.E.
Publicado en J Eur Acad Dermatol Venereol (2015)

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials

por Jemec, G.B.E., Okun, M.M., Forman, S.B., Gulliver, W.P.F., Prens, E.P., Mrowietz, U., Armstrong, A.W., Geng, Z., Gu, Y., Williams, D.A., Teixeira, H.D., Kimball, A.B.
Publicado en Br J Dermatol (2019)

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

por Zouboulis, C.C., Bechara, F.G., Dickinson‐Blok, J.L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A.B., Kirby, B., Martorell, A., Podda, M., Prens, E.P., Ring, H.C., Tzellos, T., van der Zee, H.H., van Straalen, K.R., Vossen, A.R.J.V., Jemec, G.B.E.
Publicado en J Eur Acad Dermatol Venereol (2018)